Tag Archives: ML7710

Modulight Spotlights: LASER-SHARP RESEARCH – April 2024

April 10, 2024 by Modulight Content
No comments
 Modulight Spotlights: LASER-SHARP RESEARCH – April 2024 First-in-human, phase 1 clinical trial results with ML7710 have been published in a renowned journal Radiology by Timothy Baran and team at University of Rochester Medical Center. The trial investigated treatment of deep tissue abscesses using photodynamic therapy with methylene blue and ML7710 laser. Abscesses are painful collection of pus, usually caused by a bacterial infection. Standard treatment is abscess drainage and antibiotics, however treatment responses vary widely and are linked to prolonged hospital stay, costs, and patient discomfort, as well as increasing concerns for antibiotic-resistance. The trial in 18 Continue reading →

Phototruncation cell tracking with near-infrared photoimmunotherapy using heptamethine cyanine dye to visualise migratory dynamics of immune cells

March 14, 2024 by Modulight Content
No comments
Published in: eBioMedicine Authors: Hiroshi Fukushima, Aki Furusawa, Seiichiro Takao, Siddharth S. Matikonda, Makoto Kano, Shuhei Okuyama, Hiroshi Yamamoto, Peter L. Choyke, Martin J. Schnermann, Hisataka Kobayashi  Published in: eBioMedicine Authors: Hiroshi Fukushima, Aki Furusawa, Seiichiro Takao, Siddharth S. Matikonda, Makoto Kano, Shuhei Okuyama, Hiroshi Yamamoto, Peter L. Choyke, Martin J. Schnermann, Hisataka Kobayashi A new method called phototruncation-assisted cell tracking (PACT) can be used to noninvasively track migration of immune cells to understand anti-cancer immunity mechanisms. PACT is based on irreversible photo-induced truncation reaction, transforming Cy7 into Cy5 when exposed to NIR light (780 nm). PACT was used in this study to monitor spatiotemporal migration of immune cells between tumor and Continue reading →

ML7710 for photoactivated treatment of lung cancer

March 6, 2024 by Modulight Content
No comments
Deadliest cancer Precision with photoactivation Photoimmunotherapy with ML7710 offers a clinical therapeutic option for NSCLC patients even with advanced disease stage. Besides laser light, this therapy involves photoactivated drug, which can be activated precisely at the tumor site with laser fibers, hence minimizing drug effects to healthy tissues. Smaller invasiveness compared to surgery can enable patients to stay less time recovering at the hospital. It can also be repeated if needed multiple times without cumulating toxicities, unlike radiation therapy. Some previously inoperable tumors can decrease Continue reading →Deadliest cancer Lung cancer is the leading cause of cancer deaths worldwide, with more than 2.2 million cases and 1.8 million deaths each year [1]. Lung cancer can be divided into two types, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with the latter accounting for about 85% of all lung cancer cases. NSCL is usually less sensitive to chemo- and radiotherapy and in many cases tumor cannot be removed surgically or has spread from lungs to distant sites at the time Continue reading →

Automated drug detection and dynamic measurement prioritization with medical laser platform

January 27, 2024 by Modulight Content
No comments
Published in: SPIE BIOS 2024 Authors: Henri Auvinen, Lassi Luokkanen, Zoe Ylöniemi, Natalia Leinonen, Ana Colucci, Petteri Uusimaa  Published in: SPIE BIOS 2024 Authors: Henri Auvinen, Lassi Luokkanen, Zoe Ylöniemi, Natalia Leinonen, Ana Colucci, Petteri Uusimaa Monitoring treatment through spectral data enables adjusting treatment in real-time for each patient separately, in line with the trend for personalized medicine. Modulight ML7710 laser can simultaneously measure spectral data from up to 8 different locations in tumor tissue. The laser with this optical monitoring feature is currently being tested in glioblastoma trials in Germany where patients receive photoimmunotherapy and treatment is tailored through spectral monitoring of Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – December 2023

December 28, 2023 by Modulight Content
No comments
Modulight Spotlights: LASER-SHARP RESEARCH – December 2023 Organic compounds are one of the leading causes of water pollution. Rhodamine 6G is a commonly used dye in the food and textile industries and can cause cancer when consumed in contaminated water. To tackle this problem, Professor T. Nyokong’s team at Rhodes University studied photocatalysis with ML7710 for degrading rhodamine, and showed increased degradation efficiency when photocatalysis was combined with ultrasound (sonocatalysis). This Laser-Sharp study offers a new method for more efficient degradation of organic pollutants for environmental Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – November 2023

November 14, 2023 by Modulight Content
No comments
 Modulight Spotlights: LASER-SHARP RESEARCH – November 2023 The development of modern antibiotics is recognized as one of the major achievements of medicine and has saved millions of lives. However, many infectious agents have developed resistance to antibiotics over time, and defining new antibiotic targets has been difficult since very few genes are essential for pathogens. To combat this growing problem, Professor Timothy Haystead’s team at Duke University developed a novel light-based antimicrobial strategy that targets non-essential enzyme on the surface of bacteria. Light activation was Continue reading →

Targeting Borrelia burgdorferi HtpG with a berserker molecule, a strategy for anti-microbial development

November 1, 2023 by Modulight Content
No comments
Published in: Cell Chemical Biology Authors: Dave L. Carlson, Mark Kowalewski, Khaldon Bodoor, Matthew R. Redinbo, Neil Spector, Timothy A.J. Haystead Duke UniversityPublished in: Cell Chemical Biology Authors: Dave L. Carlson, Mark Kowalewski, Khaldon Bodoor, Matthew R. Redinbo, Neil Spector, Timothy A.J. Haystead Duke University Conventional antimicrobial discovery relies on targeting essential enzymes in pathogenic organisms, contributing to a paucity of new antibiotics to address resistant strains. Here, by targeting a non-essential enzyme, Borrelia burgdorferi HtpG, to deliver lethal payloads, we expand what can be considered druggable within any pathogen. We synthesized HS-291, an HtpG inhibitor tethered to the photoactive toxin verteporfin. Reactive oxygen species, generated by light, enables Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – October 2023

October 12, 2023 by Modulight Content
No comments
 Modulight Spotlights: LASER-SHARP RESEARCH – October 2023 ​Antimicrobial resistance is an increasing healthcare problem, with new effective treatment strategies urgently needed. Professor Mitsunaga and team at The Jikei University Medical School, Japan, describe a promising treatment called photoimmuno-antimicrobial strategy (PIAS) in a new Nature publication. Detailed instructions how to design and implement the treatment are given, with Modulight’s ML7710 and ML6600 series lasers validated for drug activation in the protocol. This treatment enables targeted elimination of different microbes, regardless of the species or drug resistance Continue reading →

Photoimmunotechnology as a powerful biological tool for molecular-based elimination of target cells and microbes, including bacteria, fungi and viruses

October 4, 2023 by Modulight Content
No comments
Published in: Nature Protocols Authors: Tadayuki Iwase, Kimihiro Ito, Takashi Nishimura, Kei Miyakawa, Akihide Ryo, Hisataka Kobayashi, Makoto Mitsunaga The Jikei University School of Medicine  Published in: Nature Protocols Authors: Tadayuki Iwase, Kimihiro Ito, Takashi Nishimura, Kei Miyakawa, Akihide Ryo, Hisataka Kobayashi, Makoto Mitsunaga The Jikei University School of Medicine Microbial pathogens, including bacteria, fungi and viruses, can develop resistance to clinically used drugs; therefore, finding new therapeutic agents is an ongoing challenge. Recently, we reported the photoimmuno-antimicrobial strategy (PIAS), a type of photoimmunotechnology, that enables molecularly targeted elimination of a wide range of microbes, including the viral pathogen severe acute respiratory syndrome coronavirus 2 and the multidrug-resistant bacterial pathogen Continue reading →

Pioneering study confirms benefits of Modulight’s technology and photoimmunotherapy for ovarian cancer

September 6, 2023 by Modulight Content
No comments
A study published in Science Advances has for the first time scientifically demonstrated the potential of fluorescence-guided photoimmunotherapy enabled with Modulight’s laser platform and cloud technology. The study, a collaboration between the University of Maryland (UMD) and Modulight, confirms the benefits of targeted nanomedicine, Modulight’s medical laser system, and fluorescence-guided intervention in both achieving better treatment outcomes and predicting tumor response. “We have already published over a hundred scientific articles on our website from world-leading research groups that have used Modulight products in their studies. This Continue reading →A study published in Science Advances has for the first time scientifically demonstrated the potential of fluorescence-guided photoimmunotherapy enabled with Modulight's laser platform and cloud technology. The study, a collaboration between the University of Maryland (UMD) and Modulight, confirms the benefits of targeted nanomedicine, Modulight’s medical laser system, and fluorescence-guided intervention in both achieving better treatment outcomes and predicting tumor response. "We have already published over a hundred scientific articles on our website from world-leading research groups that have used Modulight products in their studies. This Continue reading →